MGI has announced a collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate comprehensive genomic analysis solutions tailored to Human Genetics and Pathology labs worldwide.

Key Initiatives:

• HRD Signature Validation: This initiative aims to create an automated, cost-effective solution for HRD testing using the MGI DNBSEQ-G99 sequencer. Collaborating with a Pathology Reference Lab in Spain and Agilent Technologies, MGI and SeqOne will validate a routine workflow that leverages Agilent panels, Magnis library preparation automation, MGI DNBSEQ-G99, and SeqOne’s clinically validated somaHRD signature solution. The goal is to test 96 samples and ensure the solution meets the needs of molecular pathology labs globally. This comprehensive solution will enable high-quality, efficient, and flexible HRD testing, including Genomic Instability scores and BRCA testing.

• SeqOne and MegaBOLT Integration: The collaboration aims to integrate SeqOne’s AI-powered variant identification and analysis solution with MGI’s MegaBOLT bioinformatics accelerator. MegaBOLT, a self-developed and MPS-concentrated hardware acceleration system by MGI, ensures seamless integration and compatibility with SeqOne’s platform. The combined solution will offer a versatile, cost-effective, intuitive, and time-saving process from sample to report, particularly beneficial for high-throughput Human Genetics labs working with Germline Panels, Whole Exome, and Whole Genome sequencing.

• SeqOne CE-IVD Platform Validation: This technical validation project focuses on assessing the compatibility of the SeqOne Platform with MGI sequencing data for routine diagnostics. The goal is to validate the platform's variant calling performance using a set of reference control samples, evaluating quality control, sensitivity, and precision.

Leadership Insights:

Dr. Yong Hou, General Manager of MGI Europe and Africa, expressed excitement about the collaboration, emphasizing its potential to deliver real insights and solutions for personalized healthcare. He highlighted the synergy between MGI's cutting-edge sequencing technology and SeqOne's innovative genomic analysis platform, underscoring their shared commitment to advancing genomic research and providing clinicians with tools for tailored treatments.

Martin Dubuc, CEO of SeqOne, also conveyed enthusiasm for the partnership, aligning it with SeqOne’s mission to broaden access to sophisticated genomic analysis and improve healthcare outcomes. He noted the global interest in MGI’s sequencing and bioinformatics technologies and expressed eagerness to integrate SeqOne’s CE-IVD Platform with MGI’s offerings, aiming to enhance the quality, sensitivity, and precision of bioinformatic analyses.

This collaboration between MGI and SeqOne is set to bring significant advancements in genomic analysis, offering robust solutions that cater to the evolving needs of Human Genetics and Pathology labs worldwide.